mayo clinic came recommendations fda warning citalopram description liberal regard citalopram recommendations conservative regarding escitalopram i previously reviewed problem concluded really lack data available likelihood electrocardiogram abnormalities normal clinical use citalopram cardiotoxic fda describing treat like standard antiarrhythmic drug used flecanide example practical purposes would include baseline ecgs ecgs max dose taking one level either mayo clinic fda stress test looking qtc prolongation higher heart rates elements mayo recommendations based history physical examination expecting physician knowledge drug metabolism fairly standard i thought interesting mention checking plasma levels drug especially complex cases eg patient cirrhosis responds higher recommended doses drug regarding statements selective serotonin reuptake inhibitors simply substituted one another even escitalopram citalopram generally true guys battle pbms saying drugs equivalent i found patient responded selectively citalopram escitalopram i generally able convert patients equivalent amount escitalopram next day mayo clinic fda silent molecular approaches solving problem screening patient potential risk started either drug mayo clinic offers testing cytochrome p genotypes genetic basis hereditary prolonged qtc intervals hot topic research past decade probably time expand search additional genotypes place people risk specific drug therapies approximate methods determining risk population keeping safe mayo recommendations reality based fda i think would also possible estimate risk associated taking citalopram across entire population fact point fda seems data estimate risk qtc effect risk torsade de pointes significant arrhythmia i think important patients making decision number i provide numbers rare serious antidepressant complications like serotonin syndrome federal agency perfect information patient care responsibility better george dawson md dfapa sheeler rd ackerman mj richelson nelson tk staab jp tangalos eg dieser lm cunningham jl considerations safety concerns citalopram prescribing mayo clin proc nov fda drug safety communication revised recommendations celexa citalopram hydrobromide related potential risk abnormal heart rhythms high doses